- Corporate
- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Privacy policy
- Contact us
- Subscribe
- Thank you
- Error
Increased number of shares and votes in XVIVO Perfusion AB (publ)
As of today, 30 September 2020, the total number of shares and votes in XVIVO Perfusion AB (publ) is 28,719,136. The number of shares and votes has changed as a result of the directed new issue of 2,118,640 shares that the company announced on 23 September 2020.
September 30, 2020
XVIVO Perfusion AB (publ)
For further information please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-post: dag.andersson@xvivoperfusion.com
Christoffer Rosenblad, CFO, +46 73 519 21 59 e-post: christoffer.rosenblad@xvivoperfusion.com
About Us
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2020-09-30 08:30 CEST.
